Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

IMPAKT 2017

4 - 6 May 2017
Brussels, Brussels, Belgium
Genetic determinants of breast cancer immune phenotypes
Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
Genetic determinants of breast cancer immune phenotypes ( Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )
12 May 2017
IMPAKT conference highlights
Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal
IMPAKT conference highlights ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )
12 May 2017
Mutational landscapes in pregnant and non-pregnant breast cancer
Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany
Mutational landscapes in pregnant and non-pregnant breast cancer ( Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany )
12 May 2017
Resistance to CDK4/6 inhibitors
Dr Nicholas Turner - The Institute of Cancer Research, London, UK
Resistance to CDK4/6 inhibitors ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )
12 May 2017
Deciphering the connection of genetics, immune infiltration and prognosis
Dr Jan Budczies - Charité Universitätsmedizin Berlin, Berlin, Germany
Deciphering the connection of genetics, immune infiltration and prognosis ( Dr Jan Budczies - Charité Universitätsmedizin Berlin, Berlin, Germany )
12 May 2017
Genetic vs immune strategies in breast cancer
Prof Fabrice André - Institut Gustave Roussy, Paris, France
Genetic vs immune strategies in breast cancer ( Prof Fabrice André - Institut Gustave Roussy, Paris, France )
12 May 2017
Transforming patient care through translational research
Prof Aleix Prat - Hospital Clinic of Barcelona, Barcelona, Spain
Transforming patient care through translational research ( Prof Aleix Prat - Hospital Clinic of Barcelona, Barcelona, Spain )
12 May 2017
Mechanisms of resistance to CDK4/6 inhibitors in triple negative breast cancer
Dr Uzma Asghar - The Institute of Cancer Research, London, UK
Mechanisms of resistance to CDK4/6 inhibitors in triple negative breast cancer ( Dr Uzma Asghar - The Institute of Cancer Research, London, UK )
12 May 2017
pSTAT3 in luminal breast cancer - results from BIG-2-98 trial
Dr Amir Sonnenblick - Hebrew University Medical Center, Jerusalem, Israel
pSTAT3 in luminal breast cancer - results from BIG-2-98 trial ( Dr Amir Sonnenblick - Hebrew University Medical Center, Jerusalem, Israel )
12 May 2017
Increased long-term risk of breast cancer with high intra-tumour ER hetrogeneity
Dr Linda Lindström - University of California at San Francisco, San Francisco, U...
Increased long-term risk of breast cancer with high intra-tumour ER hetrogeneity ( Dr Linda Lindström - University of California at San Francisco, San Francisco, USA )
12 May 2017
GTX-024 for androgen receptor positive breast cancer
Prof Beth Overmoyer - Dana-Farber Cancer Institute, Boston, USA
GTX-024 for androgen receptor positive breast cancer ( Prof Beth Overmoyer - Dana-Farber Cancer Institute, Boston, USA )
12 May 2017
Adaptive trial design on breast cancer
Prof Laura Vant Veer - University of California San Francisco, San Francisco, US...
Adaptive trial design on breast cancer ( Prof Laura Vant Veer - University of California San Francisco, San Francisco, USA )
11 May 2017